Business
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
New data on in-office nephrostomy tube administration of JELMYTO® (mitomycin) for pyelocalyceal solution, the only non-surgical, kidney-sparing treatment for
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\n\nNew data on in-office nephrostomy tube administration of JELMYTO® (mitomycin) for pyelocalyceal solution, the only non-surgical, kidney-sparing treatment for adults with low-grade upper tract urothelial cancer\n\n\nResults from the Phase 2b OPTIMA II trial of UGN-102 and impact of treatment in maintaining health-related quality of life\n\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN) today highlighted four presentations of interest featuring data on JELMYTO® (mitomycin) for pyelocalyceal solution for patients with low-grade upper tract urothelial cancer (LG-UTUC) and investigational agent UGN-102 (mitomycin) for intravesical solution in Phase 3 clinical development as primary non-surgical therapy for low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) at the upcoming 2022 American Urological Association (AUA) Annual Meeting, May 13-16 in New Orleans, Louisiana. The presentations will be published in the June 2022 issue of The Journal of Urology® and will be accessible via the AUA website.\n\nDetails on AUA Presentations:\n\nPodium Presentation\nAbstract #: PD26-08\nSession: Low-grade urothelial carcinoma recurs at a tempo that naturally accelerates from Adagio to Allegro\nPresenter: Alex Sankin, M.D., Associate Professor Department of Urology, Albert Einstein College of Medicine\nDate and Time: Saturday, May 14, 2022 at 2:10-2:20 PM CT\nLocation: Room 252\n\nICU Theater\nSession: Chemoablation as primary treatment: Transforming the paradigm for low grade UTUC with JELMYTO\nPresenter: Jennifer Linehan, M.D. Associate Professor of Urology and Urologic Oncology at the Saint John’s Cancer Institute\nDate and Time: Sunday, May 15, 2022 at 12:00-1:00 PM CT\nLocation: S&T Hall: Booth 1043\n\nModerated Poster\nAbstract #: MP54-06\nSession: Longitudinal Health-Related Quality of Life Outcomes in Adults with Non-Muscle-Invasive Bladder Cancer Receiving a Chemoablative Gel as a Primary Treatment (Optima II: Phase 2b, single arm, open-label trial)\nPresenter: Angela Smith, M.D., M.S. Associate Professor at the University of North Carolina (UNC) Department of Urology in Chapel Hill, North Carolina\nDate and Time: Monday, May 16, 2022 at 8:45-10:00 AM CT\nLocation: Room 228\n\nPodium Presentation\nAbstract #: PD58-06\nSession: Antegrade Administration of Reverse Thermal Mitomycin Gel for...